Last updated: October 31, 2023
Sponsor: Elpen Pharmaceutical Co. Inc.
Overall Status: Active - Recruiting
Phase
N/A
Condition
Ulcers
Scleroderma
Collagen Vascular Diseases
Treatment
N/AClinical Study ID
NCT05168215
2020-BSN-EL-128
Ages 18-90 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Adult patients
- Patients diagnosed with scleroderma (diffuse or limited)
- Patients with at least one digital ulcer, whether or not it is due to scleroderma
- Patients with 2013 ACR / EULAR Classification Criteria with a total score of ≥ 9
- Patients already taking Bosentan (Klimurtan®)
- Patients who will sign the consent form for their participation in the study
Exclusion
Exclusion Criteria:
- Patients with digital ulcers of other etiology, other than scleroderma
- Patients with severe pulmonary arterial hypertension (severe PAH- Category 3-4according to WHO)
- Patients who do not meet the criteria for taking the study drug, according to theSummary of Product Characteristics
Study Design
Total Participants: 300
Study Start date:
January 01, 2022
Estimated Completion Date:
June 01, 2024
Study Description
Connect with a study center
Laikon Hospital of Athens
Athens,
GreeceActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.